Retatrutide and NAD+ Stack to Counter GLP-1-Induced Fatigue

Some compounds in this article are sold only as research chemicals and are not labelled for human consumption. GLP-1 receptor agonists have reshaped metabolic medicine, yet a persistent complaint trails their use: a deep, sometimes disabling fatigue that settles in after dosing. The sensation is not merely sleepiness. It registers as a mitochondrial quieting, a slowing of the cellular engines that power daily life. Retatrutide (a triple agonist acting on GLP-1, GIP, and glucagon receptors) amplifies weight loss beyond single-agonist agents, but early anecdotal reports suggest it does not escape this side effect. The question becomes whether a parallel intervention, something that directly supports the electron transport chain and NAD+ pools, might offset the energy deficit without blunting the metabolic benefits. NAD+ precursors and enhancers have a long research tail in aging biology, where they intersect with sirtuins and mitochondrial quality control. Stacking them with Retatrutide is not about adding a stimulant; it is about restoring the redox and energetic baseline that GLP-1 agonism appears to depress. This article examines the mechanistic rationale, the fragmentary data, and the open questions that remain when pairing a triple incretin agonist with a core metabolic cofactor.

How GLP-1 Agonists Quiet Cellular Energy

GLP-1 receptor activation does more than suppress appetite. It shifts autonomic tone, slows gastric emptying, and, in a less discussed effect, reduces hepatic glucose output. That last action lowers circulating substrates that mitochondria rely on during fasting. The result is a cellular energy status that mimics caloric restriction, but without the adaptive upregulation of mitochondrial efficiency seen in actual fasting. In rodent models, chronic GLP-1 agonism decreases complex I activity in skeletal muscle by something like 20-30% (PubMed). Human data are thinner, but fatigue rates in semaglutide trials hover around 5-10% of participants, and real-world reports push that number higher. Retatrutide adds glucagon receptor agonism, which in theory should raise energy expenditure and hepatic fat oxidation. Yet the glucagon component also increases amino acid catabolism and may transiently drop ATP levels in hepatocytes. The net effect on perceived energy is not straightforward. What seems clear is that the incretin axis, when overdriven, creates a mismatch between perceived energy availability and actual mitochondrial output. The brain reads the signal as fatigue. The cell reads it as a need to downshift metabolism. A stack that targets the NAD+/NADH ratio could, in principle, correct that signal at its origin.

Retatrutide and the Triple-Agonist Burden

Retatrutide (LY3437943) engages GLP-1, GIP, and glucagon receptors with a potency ratio that favors GLP-1 but still drives meaningful glucagon signaling. Phase 2 data showed weight loss exceeding 20% at higher doses, with a side effect profile dominated by gastrointestinal events. Fatigue was not a primary endpoint, but it appeared in adverse event tables at rates comparable to other incretin agents. The glucagon component is the wild card. Glucagon stimulates mitochondrial uncoupling in brown adipose tissue and increases hepatic ATP demand. In a well-nourished state, this might be energizing. In a caloric deficit, which is the whole point of the drug, it can tip the balance toward energy depletion. A 2023 metabolic tracing study in mice found that chronic glucagon receptor activation lowered muscle NAD+ levels by roughly 15% after four weeks (PubMed). If that translates to humans, it suggests a direct mechanism for fatigue that is independent of caloric intake. The triple agonist thus presents a dual challenge: it reduces energy intake while simultaneously increasing energy dissipation. The NAD+ system sits at the junction of those two forces. When NAD+ drops, sirtuin activity falls, mitochondrial biogenesis stalls, and the cell enters a low-energy state that feels, subjectively, like hitting a wall. The rationale for adding an NAD+ precursor is not to override the drug but to keep the metabolic machinery idling high enough to avoid that wall.

NAD+ Precursors and the Sirtuin Connection

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme that shuttles electrons in glycolysis, the TCA cycle, and oxidative phosphorylation. It also serves as a substrate for sirtuins, a family of deacetylases that regulate mitochondrial biogenesis